A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of… (NCT00002084) | Clinical Trial Compass
CompletedNot Applicable
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
United States
Plain-language summary
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
Patients must have:
* HIV infection with CD4 counts = or \> 100 cells/mm3.
* Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
* History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
* Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
Concurrent Medication:
Excluded:
* Systemic antiherpes medication.
* Interferon.
Patients with the following prior conditions are excluded:
History of hypersensitivity to acyclovir.